Easier Access for Everyone

Making Information Accessible for Patients and Their Families

Mirum is committed to accessibility in everything we do. We value the inclusion of everyone, with consideration of their needs and challenges, and work to ensure this is shown in the experiences we design and websites we create. With this in mind, we continually take steps to improve LIVMARLIhcp.com and ensure it complies with best practices and standards.

Current Accessibility Features

Accessibility and universal usability are important parts of making informed health decisions. Rooted in our mission to transform the lives of patients and their families, the Mirum team utilizes technology, advocacy, and bold action to promote the best experiences for all audiences by employing:

  • Industry standard user-experience (UX) principles
  • Website designs with color contrast and accessibility at the forefront, according to Web Content Accessibility Guidelines (WCAG) 2
  • Inclusive design principles that celebrate the full scope of human diversity
  • Transcripts for our video content, ensuring they are accurate and complete

Our Website and Pages

Our website and landing pages are built with accessibility in mind, according to WCAG 2 best practices. The following issues are considered and remediated:

  • Title attributes for additional information when text is not available
  • Appropriate alternative text detail for images and other non-text elements
  • Graphics and interactive content
  • Form accessibility
  • Table accessibility
  • PDF and web-based brochure accessibility
  • Hierarchy
  • Line length
  • Font choice
  • Color contrast
  • Transcripts
  • Avoiding repetitive flashing in motion design

Investing in Accessibility

At Mirum, we believe it is our responsibility to ensure that content is accessible to everyone. We are dedicated to exploring new solutions, tools, and products to help enhance the overall experience. As we continue to improve our website, we will reflect those changes here within our accessibility statement and keep you informed of our efforts.

Learn More About Accessibility

The Americans with Disabilities Act (ADA)

Website accessibility standards under Title II of the ADA

Federal Communications Commission (FCC)

Twenty-First Century Communications and Video Accessibility Act

Web Accessibility Initiative (WAI)

International standards for the web to improve accessibility for people with disabilities

Web Content Accessibility Guidelines (WCAG) 2 Checklist

Compiled by Web Accessibility in Mind (Web AIM)

World Wide Web Consortium (W3C)

Strategies, standards, and resources to make the web accessible to people with disabilities

We Want to Hear From You

If you encounter any accessibility issues, please let us know. We’re here to help you get the information you need.

You can reach us by visiting the Mirum Pharmaceuticals Contact Page.

Collapse icon

Important Safety Information


LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Warnings and Precautions

Hepatotoxicity: LIVMARLI treatment is associated with a potential for drug-induced liver injury (DILI). In the PFIC trial, treatment-emergent hepatic decompensation events and elevations of liver tests or worsening of liver tests occurred. Two patients experienced DILI attributable to LIVMARLI. Two additional patients experienced DILI in the open-label extension portion of the trial. Of these 4 patients, 1 patient required liver transplant and another patient died.

In the Alagille syndrome trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred.

Obtain baseline liver tests and monitor during treatment. Liver-related adverse reactions and physical signs of hepatic decompensation should also be monitored. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue LIVMARLI if a patient experiences the following: persistent or recurrent liver test abnormalities, clinical hepatitis, or a hepatic decompensation event.

Gastrointestinal (GI) Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions. Monitor for dehydration and treat promptly. Consider reducing the dosage or interrupting LIVMARLI dosing if a patient experiences persistent diarrhea or diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever.

Fat-Soluble Vitamin Deficiency: Patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may adversely affect absorption of FSV. Treatment-emergent bone fracture events have been observed more frequently with patients treated with LIVMARLI compared with patients treated with placebo. If bone fractures or bleeding occur, consider interrupting LIVMARLI and supplement with FSV. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.

Adverse Reactions

Alagille syndrome: The most common adverse reactions are diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, and bone fractures.
PFIC: The most common adverse reactions are diarrhea, FSV deficiency, abdominal pain, liver test abnormalities, hematochezia, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI. A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

In patients with Alagille syndrome, LIVMARLI is taken once daily, 30 minutes before a meal in the morning. In patients with PFIC, LIVMARLI is taken twice daily, 30 minutes before a meal. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.